- Regeneron Pharmaceuticals press release ( NASDAQ: REGN ): Q4 Non-GAAP EPS of $12.56 beats by $2.55 .
- Revenue of $3.41B (-31.1% Y/Y) beats by $300M .
- Fourth quarter 2022 EYLEA ® U.S. net sales decreased 3% to $1.50 billion versus fourth quarter 2021.
- Fourth quarter 2022 Dupixent ® global net sales (recorded by Sanofi) increased 38% to $2.45 billion versus fourth quarter 2021 .
- "In 2023, we remain committed to achieving the full potential of our diverse commercial- and clinical-stage portfolio, with a particular focus on aflibercept 8 mg, Dupixent in a variety of type 2 allergic diseases, and our promising oncology and hematology assets."
- FY2023 , the company now expects adjusted gross margin on net product sales of 90%–92%; Capital expenditures of $825M–$950M; Non-GAAP effective tax rate of 11%–13%.
For further details see:
Regeneron Pharmaceuticals reports Q4 earnings beat; initiates FY23 guidance